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E-mail address: ks_korkmaz@yahoo.com (K.S. KorkNKX3.1 is an androgen-regulated homeobox gene that encodes a tissue-restricted transcription factor,
which plays an important role in the differentiation of the prostate epithelium. Thus, the role of
NKX3.1 as a functional topoisomerase I activity enhancer in cell cycle regulation and the DNA damage
response (DDR) was explored in prostate cancer cell lines. As an early response to DNA damage fol-
lowing CPT-11 treatment, we found that there was an increase in the cH2AX(S139) foci number and
that total phosphorylation levels were reduced in PC-3 cells following ectopic NKX3.1 expression as
well as in LNCaP cells following androgen administration. Furthermore, upon drug treatment, the
increase in ATM(S1981) phosphorylation was reduced in the presence of NKX3.1 expression, whereas
DNA-PKcs expression was increased. Additionally, phosphorylation of CHK2(T68) and NBS1(S343) was
abrogated by ectopic NKX3.1 expression, compared with the increasing levels in control PC-3 cells
in a time-course experiment. Finally, NKX3.1 expression maintained a high cyclin D1 expression level
regardless of drug treatment, while total cH2AX(S139) phosphorylation remained depleted in PC-3, as
well as in LNCaP, cells. Thus, we suggest that androgen regulated NKX3.1 maintains an active DDR at
the intra S progression and contributes to the chemotherapeutic resistance of prostate cancer cells to
DNA damaging compounds.
 2011 Elsevier Inc. All rights reserved.1. Introduction
Although androgen ablation therapy for prostate cancer leads to
decreased tumor cell proliferation and regression of tumor size [1],
the disease recurs within 2–3 years inmost organ confined prostate
cancer cases [2,3]. This recurrence may be due to developing tu-
mors retaining functional androgen receptors (AR), which allow
the tumors to respond to AR signaling events [4,5]. In these tumors,
ARs can be induced via promiscuous growth factors, which results
in transactivation of androgen-regulated genes that might signifi-
cantly affect tumor progression. The NKX3.1 gene is upregulated
by androgens via an AR dependent mechanism in normal prostate
epithelium [6,7]. It encodes a prostate- and testis-specific nucleo-
protein with two conserved domains in its wild type isoform (234
aa long). These domains are required for the interaction of
NKX3.1 with specific nuclear proteins and DNA [8]. The binding of
NKX3.1 negatively modulates AR transcription (putatively via tar-
get promoter association) and subsequent signaling events in pros-ll rights reserved.
maz).tate cells. Its expression also contributes to both cell cycle and cell
death machinery by increasing p53 acetylation and through subse-
quent stabilization of the MDM2-dependent mechanism [9]. How-
ever, as part of the Groucho complex, NKX3.1 is required to repress
transcription with its loss resulting in prostatic epithelial dysplasia
and benign hyperplasia of the rat prostate [10,11]. Ouyang et al.,
have shown that NKX3.1 suppresses tumor initiation by protecting
the cell against oxidative damage via transcriptional regulation of
the pro-oxidant enzyme levels [12,13]. TOPORS, a strong E3 ubiqui-
tin ligase, promotes proteasomal degradation of NKX3.1 through di-
rect interaction, predisposing cells to oncogenic transformation by
providing an irreversible growth advantage as the first steps in
prostate carcinogenesis [14]. Recently, it has been reported that
NKX3.1 relocates to the nucleus and enhances the cleavage and
re-ligation abilities of the topoisomerase I (topo I) enzyme through
direct association [15,16]. ATM and ATR activities are influenced by
NKX3.1 expression, which protects cells against IR- and mitomycin
C-induced DNA damage [17]. Thus, the DNA damage response is
more efficient in cells in the presence of NKX3.1 expression; this re-
port provides useful insights into our understanding of the DDR as
well as therapy resistance of LNCaP cells upon DNA damage. We
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oxidative damage and/or maintains the constitutive DNA damage
response in prostate cells through an unknown mechanism and
thus is required to suppress cancer initiation in prostate epithelia
[12,13].
In our study, CPT-11 (a semi-synthetic form of camptothecin)
was used as a damage inducer to generate ‘‘double strand’’ DNA
breaks (DSBs) during replication. In androgen-responsive (native
NKX3.1 expressing) LNCaP and in the hormone-independent pros-
tate cell line PC-3 (forced NKX3.1 expression), drug induced
H2AX(S139) and ATM(S1981) phosphorylation, as well as foci forma-
tions were investigated after short (0.5 and 4 h) and long (24 h)
exposures of CPT-11. Thus, we determined that the phosphoryla-
tion status and the foci number are regulated in prostate cells by
NKX3.1 expression in a time-dependent manner. Therefore, we
propose that as a hormone responsive factor NKX3.1 suppresses
the initiation of prostate cancer by deregulating the oxidative
stress and cell growth, which, upon DNA damage, contributes to
therapy resistance by promoting repair response and cyclin D1
expression in castration resistant prostate tumors. Considering this
evidence, NKX3.1 might be an important regulator of the DDR in
the prostate epithelium for maintaining genome fidelity against
cancer progression.2. Materials and methods
2.1. Constructs and antibodies
NKX3.1 cDNA (accession number AF249669) was used for the
construction of pcDNA4-NKX3.1 wild type (234 aa) (Invitrogen,
US) [7]. ATM, pATM(S1981), RAD50, and Cyclin D1 mouse monoclo-
nal, and DNA-PK rabbit polyclonal antibodies were purchased from
Santa Cruz Biotechnology Inc. (Bergheim, Germany). cH2AX(S139)
mouse monoclonal antibody was purchased from Millipore (US).
The NKX3.1 rabbit polyclonal antibody was a kind gift from Dr.
Fahri Saatcioglu, from University of Oslo, Norway, and the b-actin
antibody (Sigma) was a kind gift from Dr. Buket Kosova of Ege Uni-
versity, Izmir, Turkey. Alexa-fluor488- and 594-conjugated second-
ary antibodies were also purchased from Invitrogen (Carlsbad, US).
Primary and secondary antibodies were used at a concentration
range of 0.2 to 2 lg/ml.
2.2. Propagation and androgen induction
Androgen-responsive LNCaP cells (passage number 10–25)
were propagated in RPMI1640 (Invitrogen, UK) medium supple-
mented with 10% heat-inactivated FBS (Invitrogen, UK). Cells were
serum starved in the presence of 2% for 48 h and 0.5% for an addi-
tional 24 h in CT-FBS containing RPMI1640. R1881 (108 M) induc-
tions were performed for 24 h, while the cells were maintained in
serum-starved conditions [7,18,19]. Irinotecan (hereafter termed
CPT-11; Campto) (10 lg/ml) was used in all treatments for an
additional 0.5, 4 or 24 h after androgen treatment.
2.3. NKX3.1 transfection
PC-3 cells were propagated in DMEM/Ham’s F12 medium
(Invitrogen, UK), supplemented with 5% FBS, and transfection
was performed using Fugene HD (Roche, Germany) according to
manufacturer’s recommendations. Briefly, 3 ll of Fugene HD was
dissolved in 100 ll of media and incubated for 5 min. Next, 1 lg
of pcDNA4-NKX3.1 DNA was diluted into the mixture, incubated
for 15 min, and then applied to cells grown in 55 mm tissue culture
flasks drop-wise. Cells were treated for the appropriate time and
harvested for further studies.2.4. Immunoblot
Cells were lysed with ice-cold modified RIPA buffer (1% Nonidet
P-40, 50 mM Tris HCl pH 7.4, 0.25% Na-deoxycholate, 150 mM
NaCl), including 1 mM NaF, 1 mM EDTA, 1 mM Na3VO4, and com-
plete protease and phosphatase inhibitor cocktails (Roche,
Germany) unless otherwise indicated. Protein separation was per-
formed using 6–15% SDS–PAGE gels and immobilized onto PVDF
membranes (Amersham, UK and/or SantaCruz, Germany) using a
wet transfer blotter. Briefly, membranes were blocked using TBS-
T (Tris-Base-Saline containing 0.1% Tween 20) containing either
5% skim milk (w/v) or 1% BSA for anti-phospho-antibodies. Anti-
body incubations were performed using TBS-T containing 0.5%
dry milk for 1 h at RT or overnight at 4 C. Membranes were devel-
oped using 2 ml ECL plus reagent (Amersham, UK) for 5 min and
were photographed using Kodak X-ray films in a dark room.
2.5. Immunofluorescence (IF) labeling and microscopy
For the detection of cH2AX(S139) foci and NKX3.1 expression,
cells were grown on cover slips, on which transfection and treat-
ment were performed. Cells were rinsed in PBS and fixed with 4%
paraformaldehyde for 1 h at RT. Cells were then permeabilized
with 0.2% triton X-100-containing PBS and blocked for 5 min using
1% BSA in PBS buffer before incubation with primary antibodies.
Antibodies were added for 1 h, and samples were washed with
PBS twice. Secondary antibody incubations were performed at RT
for 20 min using Alexa-Fluor488/594 (anti-mouse) or Alexa-
Fluor594/488 (anti-rabbit) antibody (Invitrogen, USA). Finally, cells
were washed four times with PBS, mounted in 30% glycerol-PBS
containing DAPI (0.5 lg/ml), and analyzed immediately using a
Leica DMIL fluorescent microscope (Leica, Germany). Images were
captured using the Leica image software (LAS).
2.6. Cell growth assay
The xCELLigence System (Roche) for real-time cell analysis of
impedance-based signals was used for the quantitative determina-
tion of cell proliferation. PC-3 cells were transfected with vector or
the full length NKX3.1 expression plasmid, trypsinized 24 h after
transfection and plated into 96-well plates at three different den-
sities (2, 4, 8  103 cells/well). LNCaP cells were induced with
R1881, and cells were grown for 24 h post transfection/induction
and treated with CPT-11. The decreasing impedance was measured
in real time every 30 min according to the manufacturer’s instruc-
tions (xCELLigence, Roche, Germany) and plotted as growth rate.
2.7. Flow cytometry and analysis
Cell cycle distribution of cH2AX(S139) and pATM(S1981) was stud-
ied using flow cytometry following CPT-11 treatment in androgen-
treated LNCaP or NKX3.1 transfected PC-3 cells using a FACSCanto
(BD Biosciences, USA). Briefly, after transfection and/or treatment,
cells were collected into PBS and were fixed with 100% cold
(20 C) ethanol in a drop-wise manner. Next, cells were labeled
with specific (cH2AX(S139) and/or NKX3.1 antibody at a 1:250 or
1:500 dilution, respectively) and secondary antibody conjugated
with Alexa-flour 488 (1:1000) as described above. Bivariate read-
ings were performed subsequent to PI staining, and cH2AX(S139)
levels were plotted versus DNA content using the FacsDiva 5.0.3
software.
2.8. Image analysis and statistical calculations
Image J software was used to perform IF counts and measure-
ments [20]. Expression densities were measured for each nucleus,
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or average foci counts were classified into expression groups
depending on density, which were given in Table 1. (2) Standard
deviation and (3) p values were provided in each Fig. legend.
Where necessary, p values were calculated using Kruskal–Wallis
and Mann–Whitney tests among groups and in between pairs,
respectively.3. Results and discussion
Hormone-responsive tumors, including those of the breast,
uterus and prostate were recently reported to have alterations in
the expression of hormone responsive factors. These factors might
have roles in maintaining genome stability [21–24]. We report that
functional NKX3.1, the prostate- and testis-restricted homeobox-
containing factor, activates DNA damage response upon topoiso-
merase I inhibition in prostate cells.3.1. CPT-11-mediated cH2AX foci formation is lost in NKX3.1-
expressing cells during the S phase
We investigated the role of ectopic expression of NKX3.1 in
DNA repair. When PC-3 cells were treated with CPT-11 for 0.5, 4
or 24 h in immunofluorescence studies, the cells exhibited uniform
cH2AX(S139) foci formations, with the number of foci positively cor-
related with increasing DNA content and the time of exposure
(Fig. 1A). As the number of foci per nucleus was variable, cells were
grouped by means of cH2AX(S139) foci number, as shown in Table 1
(<1, 1–20, 20–50 and >50 foci/nucleus). In the absence of NKX3.1
expression, the baseline number of foci was <1 and increased by
38 and 54% at 0.5 and 4 h of CPT-11 treatment, respectively. The
ectopic expression of NKX3.1 significantly reduced cells with foci
by 34 and 31% after 0.5 and 4 h of CPT-11 treatment, respectively
(Fig. 1B). The average number of foci for control, vector and
NKX3.1-expressing cells were 100 ± 17, 86 ± 26 and 15 ± 14,
respectively (Fig. 1C). Control and vector-transfected cells (number
of cells; n = 8 and 66, respectively) had no significant difference in
foci number regardless of CPT-11 treatment (⁄p = 0.058). NKX3.1-
expressing cells had decreased (average) foci numbers compared
with the vector (⁄⁄p < 0.01). NKX3.1-expressing cells have a lower
proliferation rate, and CPT-11 treatment further decreased the
growth rate of both control and NKX3.1-expressing cells. These
data suggest that NKX3.1-positive cells are prone to develop che-
mo-resistance to therapy depending on exposure time and dose.
Moreover, using flow cytometry, S phase cells had higher
cH2AX(S139) and pATM(S1981) phosphorylations (highest at 24 h)
compared with S phase cells in the presence of NKX3.1 following
CPT-11 treatments (Suppl. Fig. 1). Because PC-3 cells accumulated
more in the intra S phase upon treatment (30% at 24 h), the arrestTable 1
When the counts were performed using image J software from captured images using
immunofluorescence microscopy, cells were grouped into four different categories
according to intensity observed (mean expression per cell). The cH2AX(S139) foci
count and cyclin D1 expression are categorized (average expression values from
Fig. 1B and C and Suppl. Fig. 2B and C) and plotted in terms of groups (Fig. 1B and
Suppl. Fig. 2B). (b-actin was used as a loading control. Western blots were performed
at least twice for each time course and Kruskal–Wallis and t-test statistics were
applied where appropriate).
Categories NKX3.1 and Cyclin D1 cH2AX
Mean values % of expression Mean values % of expression
+++ 40–60 65–100 15–30 50–100
++ 20–40 30–65 10–15 30–50
+ 1–20 1–30 1–10 1–30
 <1 0 <1 0observed at NKX3.1 expression was significantly suppressed (re-
duced to 14%) (Fig. 2A); furthermore, cH2AX(S139) and pATM(S1981)
were decreased (Suppl. Fig. 1 and Fig. 2B). Overall, the data suggest
that NKX3.1 has a regulatory role for genome maintenance in pros-
tate cells through activation of the DNA damage response.
3.2. DDR mediators are influenced in a time-dependent manner by
ectopic NKX3.1 expression
To investigate the role of NKX3.1 in DDR, we studied H2AX(S139),
DNA-PKcs, ATM(S1981), NBS1(S343) and CHK2(T68) expression/phos-
phorylation in PC-3 cells in the presence or absence of NKX3.1
expression. Control cells responded to CPT-11 treatment, as ob-
served by the increased phosphorylation levels of H2AX(S139),
ATM(S1891), NBS1(S343) and CHK2(T68). In comparison, NKX3.1 cells
had higher constitutive baseline levels of phosphorylation, which
were reduced in a time-dependent manner upon CPT-11 treatment
(Fig. 3A and B), suggesting that the DDR was constitutively acti-
vated upon NKX3.1 expression in the PC-3 prostate cells. Phospho-
rylations of CHK2(T68) and NBS1(S343) consistently followed changes
of pATM(S1981), while the expression of the CHK2 was not induced
until 4 h and DNA-PKcs remained constant in the absence of
NKX3.1, whereas they were profoundly increased in the presence
of NKX3.1 upon CPT-11 (Fig. 3). Additionally, cyclin D1 expression
was found decreased, leading to arrest of cell growth in the ab-
sence of NKX3.1 (Fig. 2A), which was restored with transient
expression of NKX3.1 (Fig. 3 and Suppl. Fig. 2A).
The nuclear localized cyclin D1 expression was measured
(intensity) using image J software from microscopic images. The
percentage of cells expressing cyclin D1 (with a mean intensity
>40) increased from 26 to 34% upon NKX3.1 expression. Upon
treatment with CPT-11, however, the proportion of cyclin D1
expressing cells increased from 17 to 42% and 20 to 44%, respec-
tively, at both the 4 and 24 h time points compared to controls
(Suppl. Fig. 2B). Therefore, we hypothesize that DDR in native
PC-3 cells correlates with the DNA damage status, depending on
exposure time, where the cH2AX(S139) level is kept low and nuclear
localized cyclin D1 expression is maintained at a high level by
NKX3.1 expression (Suppl. Fig. 2C). This result may be the conse-
quence of the NKX3.1-mediated enhancement of topoisomerase I
re-ligation ability and/or the interaction of HDAC1, which have
been previously reported [10]. These results demonstrate that,
upon CPT-11 mediated damage, the repair cascade works more
efficiently in cells expressing NKX3.1, whose expression is tightly
regulated via androgens in normal prostate, prostate cancer and
hormone refractory prostate tumors.
3.3. Androgen induction leads to loss of cH2AX(S139) foci formation
The occurrence of cH2AX(S139) foci was repeatedly observed as
non-uniformly distributed in LNCaP cells in the absence of andro-
gen. Following drug treatment, these cells exhibited intense
cH2AX(S139) foci, with a significant increase in the number of foci
per nucleus and a uniform distribution (Fig. 4A). When cells were
treated with the synthetic androgen R1881, the foci formations
disappeared. Moreover, when cells were treated with CPT-11 (for
4 or 24 h) in addition to androgen, the foci formations decreased
in cells in the presence of NKX3.1 (dashed circles in Fig. 4). These
data suggest that the loss of foci formation is related to androgens,
and perhaps to NKX3.1, in LNCaP cells.
Although androgen-responsive gene expression is thought to be
influenced by androgens in all cells evenly [7–9], the cells (<1%)
that have a low expression level of NKX3.1 exhibited intense foci
following drug treatment (9 and 12% for 4 and 24 h, respectively;
marked with continuous circles in Fig. 4A). Hence, this is a moder-
ate event in LNCaP cells as they are grown in culture without
Fig. 1. (A) Early (0.5) and late (4 and 24 h) response of PC-3 cells following CPT-11 treatment significantly changes depending on the DNA content in the NKX3.1-expressing
cells. cH2AX(S139) foci formation and NKX3.1 expression are visualized for each nucleus. Counter staining was performed using DAPI. (B) cH2AX(S139)-positive cells were
counted, separated into four different intensity categories, and plotted as percentages (nP 90) for control and NKX3.1-expressing cells (time course). (C) The difference in the
number of cH2AX(S139) foci after CPT-11 treatment (average foci counts = 100 ± 17; 86 ± 26 and 15 ± 14, respectively) is statistically significant for the control (p < 0.01) versus
the NKX3.1 group (n = 75, 38 and 75 nuclei, respectively), whereas it is not significant for the control versus the vector (p = 0.058). (D) Real-time quantitative determination of
cell proliferation (6 wells/point) demonstrates that PC-3 cell growth is decreased following NKX3.1 transfection (p < 0.001) and CPT-11 (48 h) treatment (p < 0.001). Arrows
indicate the time that the treatments were performed.
Fig. 2. Flow cytometry demonstrates an increase in phosphorylation of H2AX(S139) and ATM(S1981) in S phase cells in a time-dependent manner, which is abrogated by ectopic
NKX3.1 expression. (A) The percentage of cells in each cell cycle phase demonstrates that ectopic NKX3.1 expression drives cells from an intra S phase arrest, mediated by
CPT-11, and (B) NKX3.1 expression results in a significant decrease in phosphorylation levels of H2AX(S139) and ATM(S1981) in all phases of the cell cycle.
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stantial decrease in foci formation, leading to an increase in the
growth rate. We consistently observed that the LNCaP growth rate
slows for 18 h after androgen administration, which may be re-
lated to either morphological alterations or repair activation,
resulting in an increased growth rate (as measured using imped-
ance values). Although no difference was observed after 4 h of
treatment using flow cytometry (Suppl. Fig. 4A), the real-time
growth assay demonstrated that there was a significant (p < 0.01)arrest with CPT-11 treatment in LNCaP cells, regardless of andro-
gen treatment (Fig. 4B). In the presence of androgens, cH2AX(S139)
phosphorylation decreased in the G1 phase, suggesting that cells
can tolerate the DNA damage in G1/S transition, and progress
through the cell cycle (Fig. 4B).
To determine if the cH2AX(S139) phosphorylation status is re-
lated specifically to androgens, we included estrogen treatment
in our study. While androgen administration decreased the num-
ber of cH2AX(S139) foci and the phosphorylation status, estrogen
Fig. 3. (A) An ectopic NKX3.1 expression time course was performed to evaluate the early (0.5) and late (4 to 24 h) DNA damage response in PC-3 cells. DNA-PKcs, ATM(S1981),
CHK2(T68), NBS1(S343), RAD50, ATM, and H2AX(S139), as well as Cyclin D1 expression/phosphorylation levels, were studied. NKX3.1 restores the cyclin D1 expression, which
decreases after CPT-11 exposure. (B) Alterations in the expression of damage mediators are provided.
Fig. 4. (A) Double fluorescence labeling shows an inverse correlation of H2AX(S139) phosphorylation and NKX3.1 expression with synthetic androgen R1881 administration in
LNCaP cells. Dashed circles indicate the cells with high NKX3.1 expression, which do not exhibit cH2AX(S139) foci formations, whereas continuous circles indicate cells that do
not express NKX3.1. DAPI-stained nuclei define nuclear boundaries and the amount of DNA. (B) Real-time quantitative determination of cell proliferation (6 wells/data-point)
demonstrates that LNCaP cell growth is altered by androgen (p < 0.001) and CPT-11 treatment (p < 0.001). Arrows indicate the time the treatments were performed. (C) The
influence of 24 h of hormone treatment on total phosphorylation level of cH2AX(S139) is significant, which was demonstrated using western blot analysis.
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treatment may be due to the mutant (T877A) androgen receptor
LBD (ligand-binding domain), which accommodates different
hormones in LNCaP cells [25,26]. Therefore, we concluded that
treatment with androgen or estrogen either abrogates the phos-
phorylation via direct interaction or activates the DDR upon DNA
damage putatively via a hormone-responsive factor.
Thus, NKX3.1 overexpression in PC-3 cells results in a distinct
response to topo I inhibition, which was similar in LNCaP cells that
can be induced with androgens. As it was previously reported that
NKX3.1 repressed transcription together with the Groucho com-
plex [11] and regulated the pro-oxidant enzyme expressions by
HDAC1 recruitment [13], NKX3.1 may be the major regulator of
transcription, cell cycle and repair in prostate cells [16,17,21,22].
In conclusion, NKX3.1-mediated activation of DDR restores the
intra S phase arrest upon DNA damage and, consequently, leads
to reprogramming of the cells at the G1/S phase transition. This
process is controlled via an androgen action when the damage re-
sponse is constitutive. Upon exposure to DNA damage, the role of
NKX3.1 in DDR with direct interactions as well as its putative role
in histone re-organization needs to be assessed in further studies.
Acknowledgments
We would like to thank Dr. Timur Kose (Ege University, Depart-
ment of Biostatistics and Biometry) for his kind assistance with the
statistical analysis, Dr. Fahri Saatcioglu (University of Oslo, Oslo,
Norway) for providing constructs, deletion mutants and the rabbit
polyclonal a-NKX3.1 antibody, and Dr. Buket Kosova (Ege Univer-
sity, _Izmir, Turkey) for the B-actin antibody. This research was sup-
ported with grants (TUBITAK-106S200, -110S134, COST action
BM0703 CANGENIN (TUBITAK -108S288)) from the Turkish Scien-
tific and Technological Research Council and BAP projects
(06MUH004 and 10MUH006) by the Ege University to KSK.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbrc.2011.09.035.
References
[1] C. Huggins, Endocrine-induced regression of cancers, Cancer Res. 27 (1967)
1925–1930.
[2] S.R. Denmeade, X.S. Lin, J.T. Isaacs, Role of programmed (apoptotic) cell death
during the progression and therapy for prostate cancer, Prostate 28 (1996)
251–265.
[3] N. Bruchovsky, L.H. Klotz, M. Sadar, J.M. Crook, D. Hoffart, L. Godwin, M.
Warkentin, M.E. Gleave, S.L. Goldenberg, Intermittent androgen suppression
for prostate cancer: Canadian Prospective Trial and related observations, Mol.
Urol. 4 (2000) 191–199. discussion 201.
[4] Z. Culig, H. Steiner, G. Bartsch, A. Hobisch, Mechanisms of endocrine therapy-
responsive and -unresponsive prostate tumours, Endocr. Relat. Cancer 12
(2005) 229–244.
[5] T.H. Van der Kwast, J. Schalken, J.A. Ruizeveld de Winter, C.C. van Vroonhoven,
E. Mulder, W. Boersma, J. Trapman, Androgen receptors in endocrine-therapy-
resistant human prostate cancer, Int. J. Cancer 48 (1991) 189–193.[6] K.S. Korkmaz, C.G. Korkmaz, E. Ragnhildstveit, S. Kizildag, T.G. Pretlow, F.
Saatcioglu, Full-length cDNA sequence and genomic organization of human
NKX3A – alternative forms and regulation by both androgens and estrogens,
Gene 260 (2000) 25–36.
[7] J.L. Prescott, L. Blok, D.J. Tindall, Isolation and androgen regulation of the
human homeobox cDNA, NKX3.1, Prostate 35 (1998) 71–80.
[8] S.L. Zheng, J.H. Ju, B.L. Chang, E. Ortner, J. Sun, S.D. Isaacs, J. Sun, K.E. Wiley, W.
Liu, M. Zemedkun, P.C. Walsh, J. Ferretti, J. Gruschus, W.B. Isaacs, E.P. Gelmann,
J. Xu, Germ-line mutation of NKX3.1 cosegregates with hereditary prostate
cancer and alters the homeodomain structure and function, Cancer Res. 66
(2006) 69–77.
[9] Q. Lei, J. Jiao, L. Xin, C.J. Chang, S. Wang, J. Gao, M.E. Gleave, O.N. Witte, X. Liu, H.
Wu, NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer
initiation caused by PTEN loss, Cancer Cell 9 (2006) 367–378.
[10] R. Bhatia-Gaur, A.A. Donjacour, P.J. Sciavolino, M. Kim, N. Desai, P. Young, C.R.
Norton, T. Gridley, R.D. Cardiff, G.R. Cunha, C. Abate-Shen, M.M. Shen, Roles for
Nkx3.1 in prostate development and cancer, Genes Dev. 13 (1999) 966–977.
[11] C. Bowen, L. Bubendorf, H.J. Voeller, R. Slack, N. Willi, G. Sauter, T.C. Gasser, P.
Koivisto, E.E. Lack, J. Kononen, O.P. Kallioniemi, E.P. Gelmann, Loss of NKX3.1
expression in human prostate cancers correlates with tumor progression,
Cancer Res. 60 (2000) 6111–6115.
[12] B. Guan, P. Pungaliya, X. Li, C. Uquillas, L.N. Mutton, E.H. Rubin, C.J. Bieberich,
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1, J.
Biol. Chem. 283 (2008) 4834–4840.
[13] X. Ouyang, T.L. DeWeese, W.G. Nelson, C. Abate-Shen, Loss-of-function of
Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis,
Cancer Res. 65 (2005) 6773–6779.
[14] M.C. Markowski, C. Bowen, E.P. Gelmann, Inflammatory cytokines induce
phosphorylation and ubiquitination of prostate suppressor protein NKX3.1,
Cancer Res. 68 (2008) 6896–6901.
[15] C. Bowen, A. Stuart, J.H. Ju, J. Tuan, J. Blonder, T.P. Conrads, T.D. Veenstra, E.P.
Gelmann, NKX3.1 homeodomain protein binds to topoisomerase I and
enhances its activity, Cancer Res. 67 (2007) 455–464.
[16] G.L. Mayeur, W.-J. Kung, A. Martinez, C. Izumiya, D.J. Chen, H.-J. Kung, Ku Is a
Novel Transcriptional Recycling Coactivator of the Androgen Receptor in
Prostate Cancer Cells, J. Biol. Chem. 280 (2005) 10827–10833.
[17] C. Bowen, E.P. Gelmann, NKX3.1 activates cellular response to DNA damage,
Cancer Res. 70 (2010) 3089–3097.
[18] C.G. Korkmaz, K.S. Korkmaz, J. Manola, Z. Xi, B. Risberg, H. Danielsen, J. Kung,
W.R. Sellers, M. Loda, F. Saatcioglu, Analysis of androgen regulated homeobox
gene NKX3.1 during prostate carcinogenesis, J. Urol. 172 (2004) 1134–1139.
[19] K.S. Korkmaz, C.G. Korkmaz, T.G. Pretlow, F. Saatcioglu, Distinctly different
gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members
of the kallikrein family: intracellular localization, alternative cDNA forms, and
regulation by multiple hormones, DNA Cell Biol. 20 (2001) 435–445.
[20] Z. Cai, K.A. Vallis, R.M. Reilly, Computational analysis of the number, area and
density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-
hEGF or gamma-rays using Image-J software, Int. J. Radiat. Biol. 85 (2009) 262–
271.
[21] S. Hanasoge, M. Ljungman, H2AX phosphorylation after UV irradiation is
triggered by DNA repair intermediates and is mediated by the ATR kinase,
Carcinogenesis 28 (2007) 2298–2304.
[22] M.S. Huen, J. Chen, The DNA damage response pathways: at the crossroad of
protein modifications, Cell Res. 18 (2008) 8–16.
[23] I. Rappold, K. Iwabuchi, T. Date, J. Chen, Tumor suppressor p53 binding protein
1 (53BP1) is involved in DNA damage-signaling pathways, J. Cell Biol. 153
(2001) 613–620.
[24] H. Tauchi, S. Matsuura, J. Kobayashi, S. Sakamoto, K. Komatsu, Nijmegen
breakage syndrome gene, NBS1, and molecular links to factors for genome
stability, Oncogene 21 (2002) 8967–8980.
[25] J. Tan, Y. Sharief, K.G. Hamil, C.W. Gregory, D.Y. Zang, M. Sar, P.H. Gumerlock,
R.W. deVere White, T.G. Pretlow, S.E. Harris, E.M. Wilson, J.L. Mohler, F.S.
French, Dehydroepiandrosterone activates mutant androgen receptors
expressed in the androgen-dependent human prostate cancer xenograft
CWR22 and LNCaP cells, Mol. Endocrinol. 11 (1997) 450–459.
[26] S. Takahashi, T. Watanabe, M. Okada, K. Inoue, T. Ueda, I. Takada, T. Watabe, Y.
Yamamoto, T. Fukuda, T. Nakamura, C. Akimoto, T. Fujimura, M. Hoshino, Y.
Imai, D. Metzger, K. Miyazono, Y. Minami, P. Chambon, T. Kitamura, T.
Matsumoto, S. Kato, Noncanonical Wnt signaling mediates androgen-
dependent tumor growth in a mouse model of prostate cancer, Proc Natl
Acad Sci U S A 108 (2011) 4938–4943.
